Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | CASP7 | P55210 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | RGS12 | O14924 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | NOS1 | P29475 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PAH | P00439 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21009255 | 1.00 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL258405 | 1.00 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL31026287 | 1.00 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL31484058 | 0.84 | CASP7 (0.54) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL29652072 | 0.84 | CASP7 (0.54) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL14714646 | 0.83 | CASP7 (0.62) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL26499714 | 0.81 | MAPT (0.56) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL18257461 | 0.79 | KDM4E (0.43) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL18658771 | 0.79 | KDM4E (0.43) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL15325116 | 0.79 | KDM4E (0.43) | HSD17B10CASP7KDM4EMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925601-A | Application of tetrahydrobiopterin pathway as target in anti-QDPR deletion type tumor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-05-06 | — | — | CN | claimed |
| CN-119875643-A | Flashing liquid medicine and preparation method and flashing method thereof | 昆山市板明电子科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-4440342-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118714936-A | Methods and uses of microbial compositions, components or metabolites for the treatment of vagal nerve related diseases, disorders and conditions | 奇迹生物公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118265532-A | Methods and uses of microbiome compositions, components or metabolites for treating neurodegenerative diseases | 奇迹生物公司 | 2024-06-28 | — | — | CN | claimed |
| EP-2456432-B1 | COMPOSITIONS TO REDUCE OXIDATIVE STRESS | UNIV MASSACHUSETTS (US) | 2024-02-28 | — | — | EP | claimed |
| CN-117320692-A | Methods and uses of microbiome compositions, components or metabolites for treating eye disorders | 奇迹生物公司 | 2023-12-29 | — | — | CN | claimed |
| EP-4262806-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | Oxford University Innovation Limited (GB) | 2023-10-25 | — | — | EP | claimed |
| CN-116723842-A | Treatment of conditions associated with low BH4 bioavailability | 牛津大学科技创新有限公司 | 2023-09-08 | — | — | CN | claimed |
| WO-2023102149-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2022136851-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-06-30 | — | — | WO | claimed |
| US-12605386-B2 | Sapropterin formulation | APR APPLIED PHARMA RESEARCH SA (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-4658802-A1 | PROCESS FOR MAKING DRIMANE ALDEHYDES | Firmenich SA (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250339439-A1 | Sapropterin Formulation | APR APPLIED PHARMA RESEARCH SA (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-4594342-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20220096574-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS AND OTHER CONDITIONS CAUSED BY GUT MICROBIAL DYSBIOSIS | HOLOBIOME, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| CN-114032272-A | Low phenylalanine vegetable protein peptide and preparation method thereof | 中国农业大学 | 2022-02-11 | — | — | CN | disclosed |
| EP-3947633-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-107002103-B | Nostocarin-like producing microorganisms and methods of making and using the same | 小利兰.斯坦福大学托管委员会 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339439-A1 | Sapropterin Formulation | PSAP, CYP46A1, HSD11B2 | HSD17B10 154/4885CASP7 1237/4885KDM4E 4374/4885 |
| US-20220096574-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS AND OTHER CONDITIONS CAUSED BY GUT MICROBIAL DYSBIOSIS | TPH2, TPH1, HNMT | HSD17B10 426/4885CASP7 4669/4885KDM4E 1698/4885 |
| US-12605386-B2 | Sapropterin formulation | PAH, CYP46A1, CYP21A2 | HSD17B10 11/4885CASP7 641/4885KDM4E 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.